Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Retatrutide is an investigational triple-action medication that targets the GIP, GLP-1, and glucagon receptors simultaneously
Users also seem happier: Compared to non-users, our survey showed they have increased participation in activities such as exercising, socializing, shopping and engaging on social media
2017;9(410):eaai8462
The model achieved accuracies of 88.9% for GCGR (8/9 peptides correct), 100% for GLP1R (9/9 peptides correct), and 77.8% for GIPR (7/9 peptides correct)
Manufactured by Novo Nordisk, the medication is primarily a blood sugar level regulator
3 Adverse events in PIONEER 2 1,3 Comparator AE rates are not an adequate basis for comparison of safety between products 1 Because clinical trials are conducted under widely varying conditions, AE rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice 1 AE=adverse event
US$ 20.18
US$ 29.39
US$ 26.23
US$ 22.19
US$ 23.43
